|
1
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi
E, et al: Phase III study of docetaxel and cisplatin plus
fluorouracil compared with cisplatin and fluorouracil as first-line
therapy for advanced gastric cancer: A report of the V325 study
group. J Clin Oncol. 24:4991–4997. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balkwill FR, Capasso M and Hagemann T: The
tumor microenvironment at a glance. J Cell Sci. 125:5591–5596.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang SY, Song BQ, Dai SL, Yang KX, Jin Z
and Shi KW: Effects of hypoxia-inducible factor-1α silencing on
drug resistance of human pancreatic cancer cell line Patu8988/5-Fu.
Hepatogastroenterology. 61:2395–2401. 2014.PubMed/NCBI
|
|
5
|
Zhao M, Zhang Y, Zhang H, Wang S, Zhang M,
Chen X, Wang H, Zeng G, Chen X, Liu G and Zhou C: Hypoxia-induced
cell stemness leads to drug resistance and poor prognosis in lung
adenocarcinoma. Lung Cancer. 87:98–106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hockel M and Vaupel P: Tumor hypoxia:
Definitions and current clinical, biologic, and molecular aspects.
J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Röhwer N, Dame C, Haugstetter A,
Wiedenmann B, Detjen K, Schmitt CA and Cramer T: Hypoxia-inducible
factor 1alpha determines gastric cancer chemosensitivity via
modulation of p53 and NF-kappaB. PLoS One. 5:e120382010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fraser J, de Mello LV, Ward D, Rees HH,
Williams DR, Fang Y, Brass A, Gracey AY and Cossins AR:
Hypoxia-inducible myoglobin expression in nonmuscle tissues. Proc
Natl Acad Sci USA. 103:pp. 2977–2981. 2006; View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kristiansen G, Rose M, Geisler C,
Fritzsche FR, Gerhardt J, Lüke C, Ladhoff AM, Knüchel R, Dietel M,
Moch H, et al: Endogenous myoglobin in human breast cancer is a
hallmark of luminal cancer phenotype. Br J Cancer. 102:1736–1745.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kristiansen G, Hu J, Wichmann D, Stiehl
DP, Rose M, Gerhardt J, Bohnert A, Ten Haaf A, Moch H, Raleigh J,
et al: Endogenous myoglobin in breast cancer is hypoxia-inducible
by alternative transcription and functions to impair mitochondrial
activity: A role in tumor suppression? J Biol Chem.
286:43417–43428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meller S, Bicker A, Montani M, Ikenberg K,
Rostamzadeh B, Sailer V, Wild P, Dietrich D, Uhl B, Sulser T, et
al: Myoglobin expression in prostate cancer is correlated to
androgen receptor expression and markers of tumor hypoxia. Virchows
Arch. 465:419–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Behnes CL, Bedke J, Schneider S, Küffer S,
Strauss A, Bremmer F, Ströbel P and Radzun HJ: Myoglobin expression
in renal cell carcinoma is regulated by hypoxia. Exp Mol Pathol.
95:307–312. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oleksiewicz U, Daskoulidou N, Liloglou T,
Tasopoulou K, Bryan J, Gosney JR, Field JK and Xinarianos G:
Neuroglobin and myoglobin in non-small cell lung cancer:
Expression, regulation and prognosis. Lung Cancer. 74:411–418.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krishnamurthy P and Schuetz JD: The ABC
transporter Abcg2/Bcrp: Role in hypoxia mediated survival.
Biometals. 18:349–358. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Krishnamurthy P, Ross DD, Nakanishi T,
Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP and
Schuetz JD: The stem cell marker Bcrp/ABCG2 enhances hypoxic cell
survival through interactions with heme. J Biol Chem.
279:24218–24225. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mihaylova VT, Bindra RS, Yuan J, Campisi
D, Narayanan L, Jensen R, Giordano F, Johnson RS, Rockwell S and
Glazer PM: Decreased expression of the DNA mismatch repair gene
Mlh1 under hypoxic stress in mammalian cells. Mol Cell Biol.
23:3265–3273. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rodríguez-Jiménez FJ, Moreno-Manzano V,
Lucas-Dominguez R and Sánchez-Puelles JM: Hypoxia causes
downregulation of mismatch repair system and genomic instability in
stem cells. Stem Cells. 26:2052–2062. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakamura H, Tanimoto K, Hiyama K, Yunokawa
M, Kawamoto T, Kato Y, Yoshiga K, Poellinger L, Hiyama E and
Nishiyama M: Human mismatch repair gene, MLH1, is transcriptionally
repressed by the hypoxia-inducible transcription factors, DEC1 and
DEC2. Oncogene. 27:4200–4209. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Yang Y, Lu Y, Herman JG, Brock MV,
Zhao P and Guo M: Predictive value of CHFR and MLH1 methylation in
human gastric cancer. Gastric Cancer. 18:280–287. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meyers M, Wagner MW, Hwang HS, Kinsella TJ
and Boothman DA: Role of the hMLH1 DNA mismatch repair protein in
fluoropyrimidine-mediated cell death and cell cycle responses.
Cancer Res. 61:5193–5201. 2001.PubMed/NCBI
|
|
21
|
Tentori L, Leonetti C, Muzi A, Dorio AS,
Porru M, Dolci S, Campolo F, Vernole P, Lacal PM, Praz F and
Graziani G: Influence of MLH1 on colon cancer sensitivity to
poly(ADP-ribose) polymerase inhibitor combined with irinotecan. Int
J Oncol. 43:210–218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vyas S and Chang P: New PARP targets for
cancer therapy. Nat Rev Cancer. 14:502–509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Klymenko T, Brandenburg M, Morrow C, Dive
C and Makin G: The novel Bcl-2 inhibitor ABT-737 is more effective
in hypoxia and is able to reverse hypoxia-induced drug resistance
in neuroblastoma cells. Mol Cancer Ther. 10:2373–2383. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim JW, Ho WJ and Wu BM: The role of the
3D environment in hypoxia-induced drug and apoptosis resistance.
Anticancer Res. 31:3237–3245. 2011.PubMed/NCBI
|
|
25
|
Erdélyi K, Pacher P, Virág L and Szabó C:
Role of poly(ADP-ribosyl) ation in a ‘two-hit’ model of hypoxia and
oxidative stress in human A549 epithelial cells in vitro. Int J Mol
Med. 32:339–346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for research and treatment of cancer, national cancer
institute of the United States, national cancer institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Geng R, Chen Z, Zhao X, Qiu L, Liu X, Liu
R, Guo W, He G, Li J and Zhu X: Oxidative stress-related genetic
polymorphisms are associated with the prognosis of metastatic
gastric cancer patients treated with epirubicin, oxaliplatin and
5-fluorouracil combination chemotherapy. PLoS One. 9:e1160272014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi YY and He L: SHEsis, a powerful
software platform for analyses of linkage disequilibrium, haplotype
construction, and genetic association at polymorphism loci. Cell
Res. 15:97–98. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tregouet DA and Garelle V: A new JAVA
interface implementation of THESIAS: Testing haplotype effects in
association studies. Bioinformatics. 23:1038–1039. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu X, Chen Z, Zhao X, Huang M, Wang C,
Peng W, Yin J, Li J, He G, Li X and Zhu X: Effects of IGF2BP2,
KCNQ1 and GCKR polymorphisms on clinical outcome in metastatic
gastric cancer treated with EOF regimen. Pharmacogenomics.
16:959–970. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–656. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Teicher BA: Hypoxia and drug resistance.
Cancer Metastasis Rev. 13:139–168. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Galluzzo M, Pennacchietti S, Rosano S,
Comoglio PM and Michieli P: Prevention of hypoxia by myoglobin
expression in human tumor cells promotes differentiation and
inhibits metastasis. J Clin Invest. 119:865–875. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu Y, Wajapeyee N, Turker MS and Glazer
PM: Silencing of the DNA mismatch repair gene MLH1 induced by
hypoxic stress in a pathway dependent on the histone demethylase
LSD1. Cell Rep. 8:501–513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Min L, Chen Q, He S, Liu S and Ma Y:
Hypoxia-induced increases in A549/CDDP cell drug resistance are
reversed by RNA interference of HIF-1α expression. Mol Med Rep.
5:228–232. 2012.PubMed/NCBI
|
|
36
|
Teng Y, Dai D, Shen W and Liu H: Effect of
methylation of hMLH1 gene promotor on stage tumorigenesis and
progression of human gastric cancer. Zhonghua Wei Chang Wai Ke Za
Zhi. 18:166–170. 2015.(In Chinese). PubMed/NCBI
|
|
37
|
Guo H, Yan W, Yang Y and Guo M: Promoter
region methylation of DNA damage repair genes in human gastric
cancer. Zhonghua Yi Xue Za Zhi. 94:2193–2196. 2014.(In Chinese).
PubMed/NCBI
|
|
38
|
Milane L, Ganesh S, Shah S, Duan ZF and
Amiji M: Multi-modal strategies for overcoming tumor drug
resistance: Hypoxia, the Warburg effect, stem cells, and
multifunctional nanotechnology. J Control Release. 155:237–247.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Langeberg WJ, Kwon EM, Koopmeiners JS,
Ostrander EA and Stanford JL: Population-based study of the
association of variants in mismatch repair genes with prostate
cancer risk and outcomes. Cancer Epidemiol Biomarkers Prev.
19:258–264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen H, Taylor NP, Sotamaa KM, Mutch DG,
Powell MA, Schmidt AP, Feng S, Hampel HL, de la Chapelle A and
Goodfellow PJ: Evidence for heritable predisposition to epigenetic
silencing of MLH1. Int J Cancer. 120:1684–1688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Samowitz WS, Curtin K, Wolff RK, Albertsen
H, Sweeney C, Caan BJ, Ulrich CM, Potter JD and Slattery ML: The
MLH1-93 G>A promoter polymorphism and genetic and epigenetic
alterations in colon cancer. Genes Chromosomes Cancer. 47:835–844.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Raptis S, Mrkonjic M, Green RC, Pethe VV,
Monga N, Chan YM, Daftary D, Dicks E, Younghusband BH, Parfrey PS,
et al: MLH1-93G>A promoter polymorphism and the risk of
microsatellite-unstable colorectal cancer. J Natl Cancer Inst.
99:463–474. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Kim CH, Yoo YD and Lee JC: Gefitinib circumvents
hypoxia-induced drug resistance by the modulation of HIF-1alpha.
Oncol Rep. 21:801–807. 2009.PubMed/NCBI
|
|
44
|
Liu L, Sun L, Zhang H, Li Z, Ning X, Shi
Y, Guo C, Han S, Wu K and Fan D: Hypoxia-mediated up-regulation of
MGr1-Ag/37LRP in gastric cancers occurs via
hypoxia-inducible-factor 1-dependent mechanism and contributes to
drug resistance. Int J Cancer. 124:1707–1715. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Willger SD, Puttikamonkul S, Kim KH,
Burritt JB, Grahl N, Metzler LJ, Barbuch R, Bard M, Lawrence CB and
Cramer RA Jr: A sterol-regulatory element binding protein is
required for cell polarity, hypoxia adaptation, azole drug
resistance, and virulence in Aspergillus fumigatus. PLoS Pathog.
4:e10002002008. View Article : Google Scholar : PubMed/NCBI
|
